1 | NCT04197986 | Phase III | Infigratinib |
https://ClinicalTrials.gov/show/NCT04197986
|
2 | NCT02278978 | Phase II | BIBF1120 |
https://ClinicalTrials.gov/show/NCT02278978
|
3 | NCT03390504 | Phase III | Erdafitinib |
https://ClinicalTrials.gov/show/NCT03390504
|
4 | NCT03410693 | Phase II | Phase III | Rogaratinib (BAY1163877) |
https://ClinicalTrials.gov/show/NCT03410693
|
5 | NCT02608125 | Phase I | PRN1371 |
https://ClinicalTrials.gov/show/NCT02608125
|
6 | NCT02872714 | Phase II | Pemigatinib |
https://ClinicalTrials.gov/show/NCT02872714
|
7 | NCT03473756 | Phase I | Phase II | Rogaratinib (BAY1163877) |
https://ClinicalTrials.gov/show/NCT03473756
|
8 | NCT04045613 | Phase I | Phase II | Derazantinib |
https://ClinicalTrials.gov/show/NCT04045613
|
9 | NCT04003610 | Phase II | Pemigatinib |
https://ClinicalTrials.gov/show/NCT04003610
|
10 | NCT00790426 | Phase II | Dovitinib (TKI258) |
https://ClinicalTrials.gov/show/NCT00790426
|
11 | NCT04228042 | Phase I | Infigratinib |
https://ClinicalTrials.gov/show/NCT04228042
|
12 | NCT04492293 | Phase II | ICP-192 |
https://ClinicalTrials.gov/show/NCT04492293
|
13 | NCT02365597 | Phase II | Erdafitinib |
https://ClinicalTrials.gov/show/NCT02365597
|
14 | NCT03123055 | Phase I | Phase II | Vofatamab (B-701) |
https://ClinicalTrials.gov/show/NCT03123055
|
15 | NCT02052778 | Phase I | Phase II | TAS-120 |
https://ClinicalTrials.gov/show/NCT02052778
|
16 | NCT04294277 | Phase II | Pemigatinib |
https://ClinicalTrials.gov/show/NCT04294277
|
17 | NCT02401542 | Phase I | Phase II | Vofatamab |
https://ClinicalTrials.gov/show/NCT02401542
|
18 | NCT03914794 | Phase II | Pemigatinib |
https://ClinicalTrials.gov/show/NCT03914794
|
19 | NCT02393248 | Phase I | Phase II | Pemigatinib |
https://ClinicalTrials.gov/show/NCT02393248
|